Introduction
Donor T cells recognizing minor histocompatibility antigens (mHags) on recipient cells play an important role in both graftvs-leukemia (GVL) reactivity and graft-vs host-disease (GVHD) after HLA-matched allogeneic stem cell transplantation (SCT) or donor lymphocyte infusion DLI. [1] [2] [3] [4] Minor Hags are immunogenic peptides derived from polymorphic intracellular proteins. A limited number of human mHags has been characterized, including HA-1, HA-2, HA-3, HA-8, male-specific HY antigens and the mHags ACC-1 and ACC-2 encoded by distinct polymorphisms within the BCL2A1 gene. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] The large numbers of nucleotide polymorphisms in the human genome may indicate a potentially large diversity of mHags. However, mouse transplantation models have indicated that immune responses mainly occur against a limited number of mHags. [15] [16] [17] [18] In humans, little is known about the diversity of mHags to which an allogeneic immune response is directed. It has been suggested that the immune response between HLA-identical individuals is directed against a limited number of immunodominant mHags, including the hematopoietic-tissue-restricted mHags HA-1 and HA-2 and the broadly expressed HY-antigens. The postulated immunodominance of these mHags is based on the frequent detection of T cells specific for these mHags in different patients receiving SCT from their mHag disparate donors. 19, 20 However, the in vitro method most commonly used for the detection of mHag-specific T cells, is based on the generation of T-cell lines and subsequent cloning of T cells by limiting dilution. This method may preferentially select for precursor T cells with the most optimal capacity to survive and proliferate in vitro, and may not accurately reflect the variety of mHags involved in the in vivo immune response.
Recently, in patients positive for the HLA-A2-restricted mHags HA-2 and/or HA-1 who were treated with DLI from their mHagnegative donors, we showed using tetramers that the clinical immune response was associated with the presence of T cells specific for HA-2 and/or HA-1. 2 Clonal analysis of the leukemiareactive T cells showed a relatively high frequency of HA-1 and HA-2-specific T cells within the total number of leukemiareactive T cells illustrating their immunodominance. However, analyses of HLA-DR coexpression indicated a high frequency of activated T cells not specific for HA-1 or HA-2 in these patients during the clinical response. 21 These activated T cells may have been directed against other mHags expressed on cells from the recipient, including malignant hematopoietic cells, or may have been triggered by inflammatory responses resulting from infections or GVHD.
In this follow-up study, we examined the overall diversity of T cells involved in the immune response against hematopoietic cells in these patients after treatment with DLI. We exploited an assay which allowed to directly clonally isolate from peripheral blood (PB) of patients after DLI the T cells that were reactive against the patient-derived hematopoietic cells. We illustrate that the immune response to hematopoietic cells after DLI treatment is directed against multiple mHags including, but not limited to known immunodominant mHags.
Materials and methods

Donor-recipient pairs, cell collection and preparation
Three patients treated with DLI from their HLA-identical donors for relapsed multiple myeloma (patient 1) or CML (patients 2 and 3) after SCT were included in this study. After informed consent, BM was obtained from the patients before SCT, and PB was obtained after DLI. In addition, BM and PB were derived from the HLA-identical donors. Mononuclear cells (MC) were isolated by Ficoll-Isopaque separation and cryopreserved.
Phytohemagglutinin (PHA)-activated T cells (PHA blasts) and stable EBV-transformed B-cell lines (EBV-LCL) were generated as described previously. 22 
T-cell isolation
To characterize T cells that were reactive against hematopoietic cells from the recipient, T cells were enriched from PBMC using the pan T isolation kit (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). Quantities of 0.6-2.5 Â 10 6 purified T cells were cocultured with irradiated (15 Gy) BM cells isolated from the recipients pretransplant in IMDM (BioWhittaker, Verviers, Belgium) containing 10% human serum (culture medium). After 16 h of stimulation, IFNg-secreting T cells were stained using the IFNg secretion assay (Miltenyi Biotec GmbH), and isolated by single cell per well FACsorting as described previously. 21 Briefly, cells were incubated with IFNg catch reagent (anti-CD45/anti-IFNg-antibody), and cultured for 45 min at 371C. After incubation with IFNg-detection antibody, the cells were counterstained with propidium iodide (PI) (Sigma, St Louis, USA) immediately prior to cell sorting on a FACSVantage (Becton Dickinson (BD), San Jose, USA). Viable (PI-negative) IFNg-phycoerythrin (PE)-positive lymphocytes were sorted single cell per well into U-bottom microtiter plates containing 100 ml of feeder mixture consisting of culture medium, IL2 (100 IU/ml) (Chiron, Amsterdam, The Netherlands), PHA (0.8 mg/ml) (Murex Biotec Limited, Dartford, UK), and 15 Gy-irradiated allogeneic third-party PBMC (0.5 Â 10 6 /ml) and irradiated (60 Gy) patientderived EBV-LCL (0.05 Â 10 6 /ml). Proliferating T-cell clones were selected, and restimulated with feeder mixture. The nomenclature used for each T-cell clone represents the patient number followed by clone number. For flowcytometric analyses, cells were stained for 30 min at 41C with FITC-conjugated anti-CD3 (BD), PE-conjugated anti-CD4 (Caltag, Burlingame, USA) and Cy5-conjugated anti-CD8 (DAKO, Glostrup, Denmark), or with PE-labeled HLA-A2/HA-1, HLA-A2/HA-2 or HLA-B7/HY tetramers, prepared as described, 23 and analyzed on a FACSCalibur (BD). The TCR BV chain usages of the CTL clones were determined, as described. 21 The sequences of the TCRB chains were named according to the nomenclature by Arden et al.
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Analysis of cytotoxicity and cytokine production Cytotoxicity of T-cell clones was determined in standard 4 h 51 Cr release assays. 25 . As target cells, patient or donor-derived PHA blasts and EBV-LCL, and EBV-LCL from unrelated HLAidentical sibling combinations were used. Target cells were incubated with effector cells at E:T ratios ranging from 30:1 to 0 13 donorderived EBV-LCL were loaded with 10 mg/ml of peptide during labeling with 51 Cr. For analysis of IFNg and IL4 production, 5000 T cells were cocultured with 30 000 target cells. After 24 h, supernatant was harvested and the concentration of IFNg and IL4 was measured in triplicate by ELISA (CLB, Amsterdam, The Netherlands).
Hematopoietic progenitor cell inhibition assay (PIA)
To determine the capacity of T-cell clones to inhibit the growth of CD34 þ CML cells or donor hematopoietic progenitor cells (HPC) the PIA was performed. 26, 27 . As effector cells isolated Tcell clones were used. The anti-HLA-A2-specific CTL clone MBM15 served as a positive control. 28 Effector T cells were irradiated (10 Gy) to abrogate T-cell proliferation without affecting cytolytic activity. As target cells enriched CD34 þ CML progenitor cells or unfractionated CML mononuclear cells obtained from the CML patients prior to transplantation, or CD34 þ HPC purified from the donors were used. CD34 þ HPC were purified using CD34 immunomagnetic beads (Miltenyi Biotec GmbH).
Results
Donor-recipient pairs
Three patients treated for recurrence of their malignancy with DLI from their donors were studied. DLI resulted in complete remission and conversion to full donor-chimerism. All three HLA-A2-expressing donor-recipient pairs were disparate for HA-1. Pair 2 was also disparate for HY, and for the HLA-B44-restricted mHag ACC-2 encoded by the BCL2A1 gene. Pair 3 was also disparate for HA-2. The characteristics of the donorrecipient pairs, and the clinical immune responses to the DLI that occurred between 5 and 7 weeks after DLI, have previously been described in detail. 2 
Isolation of T cells reactive against patient-derived hematopoietic cells on the basis of IFNg secretion
To characterize the overall immune response against the hematopoietic cells after DLI, T cells reactive against the hematopoetic cells were isolated and directly cloned at the time of clinical response to the DLI. T cells from PB were stimulated for 16 h with irradiated BM cells derived from the patients before SCT, and activated T-cells secreting IFNg were isolated and directly cloned by single cell per well sorting. The percentages of IFNg-secreting T cells measured for patients 1, 2 and 3 after stimulation were 0.17, 0.44 and 0.06%, respectively. The numbers of T-cells analyzed were 2.5 Â 10 6 , 1 Â 10 6 and 0.6 Â 10 6 , from which 659, 674 and 632 IFNg-PE þ clonal T cells were isolated from patients 1, 2 and 3, respectively. The numbers of proliferating T-cell clones obtained after nonspecific expansion of the cloned IFNg-PE þ cells from patients 1, 2 and 3 were 189, 100 and 66, respectively, reflecting a plating efficiency of 10-30%. All 189 proliferating T-cell clones from patient 1, and 82 and 62 of the proliferating T-cell clones from patients 2 and 3 were CD8 þ T-cell clones, respectively.
Cytolytic activity of proliferating T-cell clones
To select the T-cell clones with cytolytic activity, and to determine potential differential reactivity against the patientderived hematopoietic target cells, proliferating T-cell clones were analyzed in the 51 Cr release assay for cytolytic activity against patient-or donor-derived EBV-LCL or PHA blasts. Furthermore, the T-cell clones from patients 2 and 3 were analyzed for reactivity against patient-derived CML cells and donor-derived CD34 þ progenitor cells in the PIA. From patient 1 no sufficient purified malignant cells could be obtained for analysis.
The overall numbers of CTL clones, defined as cytolytic against at least one of the patient-derived normal and/or malignant hematopoietic cells were 69, 11 and 45, representing 37, 11 and 68% of the total number of proliferating T-cell clones for patients 1, 2 and 3, respectively. No reactivity against donorderived target cells was found for any of the CTL clones, indicating alloreactive mHag specificity (data not shown). Table 1 shows the cytolytic activity of the T cell clones from patients 1-3. The CTL clones isolated from a single patient did not all show the same pattern of reactivity against the different patient-derived normal and malignant hematopoietic target cells. The majority of the 69 CD8 þ CTL clones from patient 1 lysed both patient-derived EBV-LCL and PHA blasts but three CTL clones only lysed patient-derived EBV-LCL. The 11 CD8 þ CTL clones from patient 2 were reactive against both malignant cells and EBV-LCL, whereas only five of these 11 CTL clones showed also reactivity against PHA-blasts. From the T-cell clones from patient 2 that were not cytolytic against the normal hematopoietic target cells (n ¼ 89), a random selection of 27 Tcell clones, containing both CD4 þ and CD8 þ T-cell clones, was analyzed for reactivity against the malignant cells and showed no reactivity. The 45 CTL clones from patient 3 included both CD4
þ CTL clones were only reactive against the malignant cells and the third CD4 þ CTL clone was reactive against both EBV-LCL and malignant cells. The majority of the CD8 þ CTL clones from patient 3 recognized both normal and malignant hematopoietic cells (n ¼ 26), including CTL clones with reactivity against the normal hematopoietic cells limited to EBV-LCL. Five CTL clones were only reactive against the malignant hematopoietic cells. Additionally, CTL clones only reactive with patient-derived EBV-LCL were found (n ¼ 14).
Thus, among the T cells that were reactive against the hematopoietic cells from the patient both cytolytic and noncytolytic T-cell clones were found. CTL clones isolated from a single patient varied in their reactivity against normal and malignant hematopoietic target cells indicating reactivity with distinct mHags with differential expression patterns.
Cytokine production by noncytolytic T-cell clones
To determine whether the noncytolytic T-cell clones may have contributed to the clinical immune response by the production of cytokines, a random selection of noncytolytic T-cell clones from patient 1 (n ¼ 4), patient 2 (n ¼ 6) and patient 3 (n ¼ 5) was analyzed for production of IFNg or IL4 in response to patient-or donor-derived EBV-LCL (Table 2 ). All noncytolytic T-cell clones from patient 1 produced high amounts of IFNg in response to patient-derived EBV-LCL. A limited number of the T-cell clones analyzed from patients 2 and 3 produced IFNg in response to patient-derived EBV-LCL. Some of the clones also produced IFNg in response to donor-derived EBV-LCL but in much lower amounts. Patient-specific IL4 production was only found for the CD4 þ T-cell clone 62 from patient 3.
Determination of HLA class I restriction elements
To determine whether the CD8 þ CTL clones showed classical HLA class I restricted recognition, a selection of CD8 þ CTL clones from patient 1 (n ¼ 4), patient 2 (n ¼ 4) and patient 3 (n ¼ 5) was analyzed, showing that lysis by all CD8 þ T-cells clones was blocked by anti-HLA class I antibodies but not by anti-HLA class II antibodies (data not shown).
To analyze whether different HLA class I-restricting elements were used by the CD8 þ CTL clones isolated from each patient, CTL clones from which sufficient cells could be obtained were analyzed for reactivity against a panel EBV-LCL from unrelated individuals that shared only a single HLA molecule with the recipient. The CTL clones that were only reactive against the leukemic cells could not be further analyzed for logistical reasons.
The HLA-restricting elements of the CD8 þ CTL clones are summarized in Table 3 . A variety of HLA-restricting elements was found to be used by the CTL clones isolated from a single patient. For patient 1 CTL clones with HLA-A2-restricted recognition (n ¼ 54) as well as CTL clones with HLA-B7-restricted recognition (n ¼ 2) were found. Within the CTL clones from patient 2, CTL clones with HLA-A2 (n ¼ 1), HLA-B44 Table 1 Reactivity of proliferating T-cell clones from patients 1-3 against patient-derived normal and malignant hematopoietic target cells In all, 27 of the 89 T-cell clones from patient 2 that did not lysis PHA blasts or EBV-LCL could be analyzed for reactivity against leukemic cells, showing no reactivity.
(n ¼ 2) or HLA-B7 (n ¼ 5)-restricted recognition were identified. Within the CTL clones from patient 3, CTL clones with HLA-A2-restricted (n ¼ 14), HLA-B8-restricted (n ¼ 1) or HLA-B60 (n ¼ 2)-restricted recognition were found. For a limited number of CTL clones the HLA-restriction could not be identified.
CTL clones with the same HLA-restricting element are diverse in mHag specificity
To determine whether the CTL clones from a single patient that used the same HLA-restricting element recognized diverse mHags, the specificity of these CTL clones was analyzed by labeling with peptide-specific tetramers and using panels of EBV-LCL that expressed the relevant HLA molecule. The panels of EBV-LCL consisted of 10-14 unrelated EBV-LCL expressing the relevant HLA-restricting element, allowing to estimate the population frequency of the mHag.
Of the 54 HLA-A2 restricted CTL clones from patient 1, 19 were HA-1 specific as determined by tetramer staining (data not shown). From the remaining 35 CTL clones 33 clones showed an identical reaction pattern (Type 1 CTL clones) (Figure 1a) . The two other CTL clones (Types 2 and 3) showed different reactivities (Types 2 and 3 CTL clone) (Figure 1b and c) . None of CTL reacted with HA-8 peptide (data not shown). All three types of HLA-A2-restricted CTL clones showed differential recognition of unrelated donor-recipient pairs, further illustrating mHag specificities, with population frequencies of 57, 67 and 50%, respectively. The two HLA-B7-restricted CTL clones from patient 1 showed similar recognition patterns, with a population frequency of 27% (data not shown).
For the CTL clones from patient 2, tetramer staining showed that the HLA-A2-restricted CTL clone was HA-1 specific, and that four of the five HLA-B7-restricted CTL clones were specific for HY-B7 (data not shown). The remaining HLA-B7-restricted CTL clone was directed against a mHag with a population frequency of 50% (data not shown). The two HLA-B44-restricted CTL clones from patient 2 showed different reactivity patterns (Figure 2a and b) . CTL clone 2.65 but not CTL clone 2.37 was specific for the mHag ACC-2 (KEFEDDIINW) (Figure 2c) .
The HLA-A2-restricted CTL clones from patient 3 were specific for HA-1 (n ¼ 1) or HA-2 (n ¼ 13) (data not shown). The two HLA-B60-restricted CTL clones 3.16 and 3.25 from patient 3 showed different reactivity patterns, with population frequencies of 63 and 31%, respectively (data not shown).
These data show that the CTL clones within each patient that shared the same HLA-restricting element were directed against distinct mHags, and that the immune responses against the hematopoietic cells in patients 1, 2 and 3 were directed against at least five different mHags with variable population frequencies. Table 2 Production of IFNg and IL4 by non-cytolytic T-cell clones from patients 1-3 in response to patient-or donor-derived EBV-LCL To determine whether the CTL clones with similar mHag specificity that were present in high frequencies differed in clonal origin, the TCR BV chains of the Type 1 CTL clones and the HA-1-specific CTL clones from patient 1, and of the HA-2-specific CTL clones from patient 3 were determined (Table 4 ). Only CTL clones from which T-cell samples free of irradiated allogeneic feeder cells could be obtained were analyzed. The 20 Type 1 CTL clones analyzed from patient, all used the BV7 chain. Sequencing of the TCRB chain of a random 10 CTL clones showed the same BV7S1A1 TCR. Within the HA-1-specific CTL clones from patient 1, two types of BV6S4 TCR were found. Among 4 HA-2-specific CTL clones analyzed from patient 3, three different TCR were found.
CTL clones with variable proliferative capacity were isolated
To determine whether the proliferative capacity of the CTL clones isolated from a single patient varied, the numbers of cells obtained from the CTL clones from patients 1 to 3 were determined following an identical expansion period of 23 days after clonal isolation (Figure 3) . A large variation in proliferative capacity was found among the CTL clones. Furthermore, a number of single mHag specificities with low proliferative capacity were isolated, such as the HLA-A2-restricted Type 3 CTL clone 1.21 from patient 1 and the BCL2A1/B44 mHag-specific CTL clone 2.65. 
Discussion
We analyzed the diversity of the immune response against hematopoietic cells in three patients who received DLI from their HLA-identical donors, resulting in complete remission of the disease and restoration of full donor chimerism. The T cells involved in the immune response against the hematopoietic cells in these patients were diverse at multiple levels, including phenotype, cytolytic activity and proliferative capacity. Almost all CTL clones were CD8 þ and showed HLA class I-restricted cytotoxicity. CTL clones within a single patient were directed against multiple distinct mHags that varied in their expression pattern on normal and malignant hematopoietic cells. The mHags included the immunodominant mHags for which the disparities were known to be present in the donor-recipient pairs as well as other mHags. CTL clones directed against some mHags were frequently present, and TCR BV analysis showed that these mHag-specific CTL clones were of monoclonal or oligoclonal origin.
T cells reactive against the patient-derived hematopoietic cells were directly isolated and cloned from PB derived from the patients at the time of a clinical response to DLI, on the basis of IFNg secretion by the T cells after stimulation with BM cells derived from the patient pretransplant. Since especially CD4 þ T cells of the Th1 phenotype, which produce IFNg, are thought to provide help for CTL generation, the isolation on the basis of IFNg would allow isolation of both CD8 þ T cells and CD4 þ T cells participating in the clinical immune response. Since the BM cells used for stimulation contained both malignant and nonmalignant hematopoietic cells, the clonally isolated T cells can be directed against malignancy-specific or hematopoiesisassociated antigens. Only a small fraction of the circulating T cells was reactive against the patient-derived hematopoietic cells, as was indicated by the percentages of IFNg secreting T cells after stimulation (o0.5%). The clonally isolated T cells were expanded by nonspecific stimulation to reduce the risk of selective isolation of a limited repertoire, and both T-cell clones with limited and with extensive proliferative capacity were isolated. In this way, the T-cell clones obtained from each patient represented a cross-section of the overall immune response against the cells of hematopoietic origin, and could be used to study the T-cell diversity within this immune response.
Both CD4 þ T-cell clones and CD8 T-cell clones were present but the majority of the proliferating T-cell clones was CD8
þ . This correlated with the high percentages of CD8 þ T cells within the responder T-cell populations from which the IFNg secreting T cells were cloned (58-93%). Furthermore, the in vivo immune response may have been dominated by CD8 þ T cells, as was indicated in our previous study by the strong increase in percentages of HLA-DR þ T cells within the CD8 þ T-cell populations and a more limited increase within the CD4 þ T-cell populations after DLI. 21 This does not rule out a role for CD4
þ T cells in a more early phase of the in vivo immune 
The last three residues of the V-region are shown, followed by the N-region and the first three residues of the J-region. a In all, 20 Type 1 CTL clones were analyzed for TCR BV chain usage by PCR, showing TCR BV7 for all 20 clones; DNA sequence analysis was performed for a random 10 of these CTL clones.
Figure 3
Variable proliferative capacities of the characterized CD8 þ CTL clones from patients 1-3. The numbers of cells obtained for each CD8
þ CTL clone were determined following an identical period of 23 days after clonal isolation. The different symbols represent the different mHag specificities that were isolated from the three patients: the HA-1-specific CTL clones (K) from patients 1-3, the HLA-A2-restricted Type 1 CTL clones (&), Type 2 CTL clone 1.15 ('), Type 3 CTL clone 1.21 (E), and the HLA-B7 restricted CTL clones 1.173 and 1.183 (F) from patient 1, the HY-B7-restricted CTL clones ( þ ), the ACC-2 specific CTL clone 2.65 (m) and the HLA-B44-restricted CTL clone 2.37 ( Â ) from patient 2, and the HA-2-specific CTL clones (J), the HLA-B8-restricted CTL clone 3.41 (B) and the two different HLA-B60-restricted CTL clones 3.16 and 3.25 (n) from patient 3. response and, alternatively, the limited numbers of CD4 þ T-cell clones isolated may be because CD4 þ T cells may have produced cytokines other than IFNg . Furthermore, the relatively inferior expression of HLA class II molecules on the hematopoietic stimulator cells may have induced lower activation of CD4 þ T cells. With respect to the in vivo immune response against the hematopoietic cells these data showed that a large number of the T cells may not only have contributed to the GVL response, but also to the establishment of full donor chimerism. The noncytolytic T-cell clones may have contributed to the in vivo immune response by providing critical T-cell help for the development of cytolytic T cells through the secretion of cytokines ( Table 2) .
The specificity analysis of the CTL clones showed that the in vivo immune response against the hematopoietic cells consisted of T cells directed against multiple distinct mHags. In addition to CTL clones directed against the immunodominant mHags HA-1, HA-2 or HY-B7, CTL clones specific for several other mHags were isolated, although, except for the Type 1 CTL clones, at limited frequencies. Apparently, the in vivo immune response is not just directed against a single or a limited number of immunodominant mHags as may have been suggested by previous in vitro studies using the conventional method for the analysis of mHag-specific T-cell responses.
Based on the large numbers of specific CTL clones isolated, the immune responses against HA-1 and the Type 1 mHag in patient 1, HY-B7 in patient 2, and HA-2 in patient 3 probably contributed significantly to the in vivo immune response against the hematopoietic cells. The TCR BV chain usage indicated that these mHag-specific T-cell responses were of monoclonal or oligoclonal origin. The immune responses against the other mHags may also have contributed significantly to the in vivo immune response, despite the relatively limited numbers of mHag-specific CTL clones isolated. Due to differential kinetics in the mHag-specific immune response to DLI in vivo, the number of isolated T cells specific for a certain mHag may vary depending on the timepoint of isolation after DLI. 2 One of the mHag specificities for which only a single specific CTL clone was isolated, was the recently characterized HLA-B44-restricted mHag ACC-2 that is encoded by the BCL2A1 gene. 13 Since T cells specific for BCL2A1 have now been identified in at least three separate donor-recipient pairs, this mHag may also be immunodominant.
The direct cloning technique may be an important tool for the isolation of T cells specific for new mHags, thereby contributing to the identification of new mHags. The process of molecular characterization of mHags itself, requiring large cell numbers of the CTL clone of interest, is also facilitated since the proliferative capacity of the directly cloned T cells can all be used for clonal expansion resulting in the generation of large cell numbers of the CTL clones. The direct isolation technique may also be usefull for the generation of large numbers of mHag-specific T cells for adoptive immunotherapy.
Our finding that multiple distinct mHags are involved in the immune response against hematopoietic cells after treatment with DLI may have important implications for the application of adoptive immunotherapy with mHag-specific T cells. The combination of the immune responses against different mHag specificities may evoke a more powerfull overall immune response than an immune response against a single mHag. Therefore, adoptive immunotherapy with T cells specific for several different mHags may result in more effective eradication of the leukemic cells as compared to treatment with T cells specific for a single mHag.
In conclusion, using a direct cloning technique we show that the immune response to the hematopoietic cells after DLI treatment is directed against a variable repertoire of mHags. In addition to T cells directed against known immunodominant mHags, T cells directed against multiple distinct mHags may significantly contribute to the in vivo immune response.
